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Abstract
Proteolysis targeting chimeric molecules (Protacs) target proteins for destruction by exploiting the 
ubiquitin-dependent proteolytic system of eukaryotic cells.We designed two Protacs that contain 
the peptide ‘degron’ from hypoxia-inducible factor-1α, which binds to the Von –Hippel–Lindau 
(VHL) E3 ubiquitin ligase complex, linked to either dihydroxytestosterone that targets the 
androgen receptor (AR; Protac-A), or linked to estradiol (E2) that targets the estrogen receptor-α 
(ERα; Protac-B). We hypothesized that these Protacs would recruit hormone receptors to the VHL 
E3 ligase complex, resulting in the degradation of receptors, and decreased proliferation of 
hormone-dependent cell lines. Treatment of estrogen-dependent breast cancer cells with Protac-B 
induced the degradation of ERα in a proteasome-dependent manner. Protac-B inhibited the 
proliferation of ERα-dependent breast cancer cells by inducing G1 arrest, inhibition of 
retinoblastoma phosphorylation and decreasing expression of cyclin D1, progesterone receptors A 
and B. Protac-B treatment did not affect the proliferation of estrogen-independent breast cancer 
cells that lacked ERα expression. Similarly, Protac-A treatment of androgendependent prostate 
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cancer cells induced G1 arrest but did not affect cells that do not express AR. Our results suggest 
that Protacs specifically inhibit the proliferation of hormone-dependent breast and prostate cancer 
cells through degradation of the ERα and AR, respectively.
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Introduction
Prostate cancer is the second most common type of cancer diagnosed in men (Culig et al., 
2003; Parkin et al., 2005). Breast cancer is the most common cancer diagnosed in women, 
which represent 14% of all female cancer deaths (Parkin et al., 2005). The pathogenesis of 
prostate and breast cancer has been clearly linked to hormone stimulation of the androgen 
receptor (AR; Huggins, 1967) and the estrogen receptor-α (ERα), respectively (Ellis et al., 
2001; Buzdar, 2003). Hormonal and systemic chemotherapy are used for metastatic breast 
and prostate cancer (Ellis et al., 2001; Buzdar, 2003). Although 66%of breast tumors express 
ERα and 70% of these respond to hormone therapy, metastatic disease has a very low cure 
rate and eventually leads to hormone refractory disease despite expression of ERα in 30% of 
refractory tumors (Clarke et al., 1996). In prostate cancer, the majority of patients (85%) will 
have an initial favorable response to hormone therapy, however eventually hormone 
refractory disease occurs approximately 18–24 months after the start of therapy, and most 
patients succumb to their disease (Santen, 1992; Savarese et al., 2001). Hormone-resistant 
disease is acquired in over 50% of the cases through molecular and cellular changes that 
alter the normal activation of the AR and allow prostate cancer cells to grow despite 
physiologically low serum testosterone levels (Culig et al., 1994; Gaddipati et al., 1994; 
Bubendorf et al., 1999; Craft et al., 1999; Taplin et al., 1999; Godoy-Tundidor et al., 2002; 
Ueda et al., 2002; Bakin et al., 2003; Franco et al., 2003). Mechanisms of hormone 
resistance include overexpression, mutation, or indirect activation of AR. Interestingly, the 
AR continues to be expressed and is required for cell growth and survival (Linja et al., 2001; 
Eder et al., 2002; Zegarra-Moro et al., 2002; Liao et al., 2005). Presently, there is no 
effective treatment for androgen refractory disease (Thiele et al., 1999; Moul, 2000).
Considering the importance of the expression and activity of hormone receptors in breast 
and prostate cancer, we designed a new approach to treatment. This technology, which is 
based on heterobifunctional small molecules known as proteolysis targeting chimeric 
molecules (Protacs), exploits the unique characteristics of the ubiquitin proteasome system 
in eukaryotic cells. Protacs are bridging molecules that recruit a ubiquitin ligase (E3) to the 
target of interest. These heterobifunctional small molecules contain two moieties; the first 
moiety (degron) binds to a ubiquitin ligase, whereas the second moiety is a ligand for the 
target that will be degraded. Consequently, when these moieties are joined, they link the 
target to a ubiquitin ligase, resulting in ubiquitination and degradation of the target (Figure 
1a). In prior work, we established ‘proof of principle’ that Protacs are effective in vitro to 
recruit proteins for ubiquitination and degradation (Sakamoto et al., 2001). We also showed 
that Protacs based on the IκBα peptide can induce the ubiquitination of purified ERα and 
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degradation of GFP-AR expressed in 293 cells, but only when these Protacs were 
microinjected into cells (Sakamoto et al., 2001, 2003). To develop Protacs for in vivo 
application, a cell permeable version of Protac was synthesized (Schneekloth et al., 2004). 
The previously used degron (IκBα) required phosphorylation on two serine residues to be 
recognized by SCFβ–TRCP (Karin and Ben-Neriah, 2000), which made the resulting 
Protacs relatively impermeable and susceptible to phosphatases. To avoid this problem, the 
IKBα peptide was replaced by a hydroxyproline-containing peptide from hypoxia-inducible 
factor-1α (HIF-1α), which is recognized by the Von –Hippel–Lindau (VHL) ubiquitin 
ligase complex and is not dependent on phosphorylation (Kim and Kaelin, 2004; 
Schneekloth et al., 2004; Bargagna-Mohan et al., 2005). These Protacs contain a 
pentapeptide degron from HIF-1α (Bargagna-Mohan et al., 2005), linked to 
dihydroxytestosterone (DHT) to target the AR (Protac-A), or linked to estradiol (E2) to 
target the ERα (Protac-B; Figure 1b). We hypothesized that these Protacs should be cell 
permeable and induce degradation of AR or ERα, respectively. In this paper, we report that 
these two Protacs lead to ubiquitination and degradation of endogenous AR and ERα. The 
reduction of receptor protein levels occurs through a proteasome-dependent pathway, and 
induces cell cycle and growth arrest in hormone-dependent but not hormone-independent 
tumor cell lines.
Results
Specific effect of Protac in hormone-dependent cell lines
We used the lymph node carcinoma of prostate (LNCaP) cell line as the androgen-dependent 
prostate cancer model. LNCaP cells express the AR and can only proliferate in medium that 
contains androgens (Supplementary Figure S1A). As a negative control, we used PC-3 and 
DU-145 cells, which are both androgen independent and do not express AR (Supplementary 
Figure S1A). For the breast cancer model, we used MCF-7 and T47D as hormone-dependent 
cell lines, and SKBr3 as the hormone-independent cell line (Supplementary Figure S1B). 
SKBr3 does not express ERα. As MCF-7, T47D and LNCaP cells are hormone dependent, 
we hypothesized that treatment with Protac would affect the growth of these cells. In both 
breast and prostate cancer models, the proliferation of hormone-dependent cell lines was 
inhibited by Protac treatment. Protac-A (DHT-Protac) affected the proliferation of LNCaP 
cells (IC50(72 h)=12.5 μM, IC50(144 h)= 1.52 μM) whereas androgen-independent PC-3 
(Figure 2a) or DU-145 cells (data not shown) were not affected at the same concentrations, 
which suggests that Protac-A is specific for its target. We also investigated the effect of DHT 
on the proliferation of LNCaP cells (Figure 2a), when used at the IC50 of Protac-A (12.5 
μM), DHT had no effect on LNCaP cell proliferation. Therefore, Protac-A requires the 
peptidic moiety (HIF1α pentapeptide degron) to inhibit LNCaP cell proliferation. The same 
specificity was observed in breast cancer cells, where the proliferation of estrogendependent 
cell lines (MCF-7 and T47D) was inhibited by Protac-B treatment (IC50(72 h)=50 μM and 
IC50(72 h)=16 μM, respectively), but there was no effect on proliferation by treatment with 
estradiol (Figure 2b). Meanwhile, proliferation of the estrogen-independent cell line SKBr3 
was not affected by Protac-B (Figure 2b). The reduction in proliferation of hormone-
dependent (but not hormone-independent) cell lines treated with Protacs is presumably 
because of downregulation of hormone receptor. To test this hypothesis, we examined by 
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western blot analysis the levels of hormone receptor in cells treated with Protac. We 
observed a significant decrease in the levels of AR and ERα at Protac concentrations that 
inhibited proliferation (Figure 2c).
Protacs induce ubiquitination and proteasome-dependent degradation of the targeted 
hormone receptors
One of the advantages of Protacs is their target specificity. The specificity is conferred by the 
target-binding ligand, DHT in the case of Protac-A (targeting AR) and 17β-estradiol in 
Protac-B (targeting ERα; Figure 1b). As an example of this specificity, AR protein levels 
were not affected by treatment of LNCaP cells with the ERα-specific Protac-B (Figure 3a). 
We next investigated the mechanism by which Protacs brought about decreases in AR and 
ERα levels. In both MCF-7 and T47D cells, the proteasome inhibitor MG132 blocked 
downregulation of ERα by Protac-B (Figure 3b). These results suggest that Protac-B 
activates degradation of ERα by the proteasome.
To determine whether Protac-dependent turnover of ERα and AR involves 
polyubiquitination, we immuno-precipitated ERα from breast and AR from prostate cancer 
cells, respectively, following treatment with Protac and MG132 (Figures 3c and d). The 
immunoprecipitates were subsequently blotted with anti-ubiquitin to assess the levels of 
ubiquitin-conjugated ERα. ERα ubiquitination increased in the presence of Protac-B and 
proteasome inhibitor (MG132) in comparison to treatment with proteasome inhibitor alone 
(Figure 3c). This suggests that ERα degradation in treated cells is because of a Protac-
dependent increase in receptor ubiquitination. Similarly, enhanced ubiquitination of AR 
ubiquitination was observed in prostate cancer cells treated with Protac-A (Figure 3d).
Our prior data indicated that treatment with Protacs based on the HIF1α resulted in 
degradation of their targets through association with the VHL E3 ligase. To address whether 
recruitment of VHL activity to ERα by Protac-B competes with the ubiquitination and 
degradation of endogenous HIF1α, we examined HIFα levels in cells treated with this 
Protac. HIFα levels did not increase in cells treated with Protac-B but did increase in cells 
treated with proteasome inhibitor (Figure 3b). Thus, the effect of Protac on the proliferation 
of hormone-dependent cell lines correlates with downregulation of the targeted receptor and 
does not appear to depend on accumulation of the VHL substrate HIF1α.
The induction of targeted receptor degradation by Protac treatment inhibits receptor 
signaling, leading to cell cycle arrest
To understand the mechanism by which Protac inhibits breast and prostate cancer cell 
proliferation, we investigated the expression of known target genes activated by ERα, cyclin 
D1 and progesterone receptor (PR) (Klein-Hitpass et al., 1988; Savouret et al., 1991; Butt et 
al., 2005). Treatment of estrogen-dependent cells with Protac-B resulted in decreased 
expression of cyclin D1 and PR concomitant with decreased ERα levels (Figure 4a). 
Consistent with the idea that Protacinduced turnover of hormone receptors silences 
downstream signaling pathways that drive tumor cell proliferation, treatment of breast and 
prostate cancer cells with Protacs resulted in dephosphorylation of the retinoblastoma (Rb) 
protein (Figures 4a and b) and cell cycle arrest in G1 (Figure 4b). Rb is a critical regulator of 
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the G1/S transition and its activation by dephosphorylation leads to a cell cycle arrest in G1. 
We also observed a dose-dependent dephosphorylation of Rb at 72 h in Protac-treated 
LNCaP and MCF-7 cells (data not shown). To address the specificity of the molecular 
responses to Protacs, we tested whether they can be reversed by the addition of competitor 
steroid hormone. We treated MCF-7 and T47D cells with 50 μM of Protac-B and 50 μM of 
estradiol (Figure 4a). In both cases, we observed that treatment of cells with estradiol and 
Protac resulted in minimal or no downregulation of cyclin D1, PR A and B, and phospho-
Rb. Similarly, we could block effects of Protac-A treatment on Rb phosphorylation in 
prostate cancer LNCaP cells by simultaneously treating with a 10-fold excess of DHT 
(Figure 4b).
Although simultaneous treatment with Protac and hormone reversed the inhibitory effect of 
Protacs on ERα and AR function, the addition of hormone did not block downregulation of 
the hormone receptors. This is likely because of the fact that steroid hormones induce 
turnover of their receptors. In particular, the estradiolinduced degradation of ERα has been 
studied in detail (Wijayaratne and McDonnell, 2001). Estradiol-induced turnover of ERα is 
intimately linked to ERα function and thus is tightly correlated with ERα activity. On the 
other hand, ectopic degradation of hormone receptors induced by Protacs is unlikely to be 
linked to receptor-dependent transcription, and thus is not expected to correlate with ERα 
function.
To determine the durability of the antagonistic effect of Protacs, we investigated the effects 
of prolonged Protac treatment on prostate and breast cancer cells. After 6 days of continuous 
Protac treatment, proliferation of LNCaP cells was still inhibited and there were fewer viable 
cells than after 3 days of treatment (Figure 4c). These data suggest that prolonged treatment 
with Protac may be cytotoxic and induce apoptosis. The same extended treatment did not 
affect the proliferation of androgen-independent PC-3 cells (data not shown). This result is 
in agreement with observations reported by other groups that AR is important for the 
proliferation and survival of hormone-dependent prostate cancer cells (Linja et al., 2001; 
Eder et al., 2002; Zegarra-Moro et al., 2002; Liao et al., 2005). Previously published work 
demonstrated that siRNA against AR resulted in apoptosis, however, only after 4 days. 
Therefore, prolonged treatment of Protac may have additional advantages of activating 
apoptosis in prostate and breast cancer cells.
Rationale for the design of new Protacs
Several possibilities can be envisioned to improve the activity and specificity of Protacs. 
Targeting new proteins would require a change in the ligand moiety. Protac activity can also 
be modulated by altering membrane permeability or the affinity for the E3 ligase. Reports 
have demonstrated that addition of a polyarginine sequence to peptides enhances cellular 
entry (Kirschberg et al., 2003). To increase cell permeability of Protac, a polyarginine tail 
and two glycine residues were added (Figure 5a; Kirschberg et al., 2003). To evaluate 
interaction of polyarginine-containing ligand with VHL, we employed a fluorescence 
polarization assay to measure the ability of the new peptide to compete out binding of a 
fluorescently labeled HIF-1α degron peptide (Asp-Glu-Ala-Leu-Ala-Pro(OH)-Tyr-Ile-Pro-
Asp) to VHL (Figure 5b). The addition of a polyarginine tail did not compromise the affinity 
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of pentapeptide for VHL (pentapeptide-G-G-(arg)9: Leu-Ala-Pro(OH)-Tyr-Ile-Gly-Gly-(D-
Arg)9, Ki=0.026 μM; Figure 5b); in fact, affinity was enhanced by ~17-fold compared to the 
natural hydroxyproline-containing pentapeptide. As a negative control, we used a mutant 
pentapeptide (mutant pentapeptide-G-G-(Arg)9: Leu-Ala-Ala-Tyr-Ile-Gly-Gly-(D-Arg)9) 
lacking the critical hydroxyproline ligand. The mutant peptide did not detectably bind VHL 
(Figure 5b). Finally, we measured the affinity of the new Protac (Protac-AA) for VHL 
(Figure 5b). This new molecule consists of DHT as the ligand and the peptide (pentapeptide-
G-G-(Arg)9: Leu-Ala-Pro(OH)-Tyr-Ile-Gly-Gly-(D-Arg)9) as the degron that is recognized 
by VHL (Figure 5a). The affinity of this Protac for VHL was very similar to the control 
HIF1α peptide with Ki=0.341 and 0.458 μM, respectively. Thus, we would expect an 
improvement of the activity of the Protac-AA over the Protac-A because of the expected 
enhancement in cell permeability.
Protac-AA activity in prostate cancer cell lines
To test the effects of Protac-AA, we treated prostate cancer cell lines LNCaP and PC3 for 72 
h (Figure 6). The new peptide increased the activity of Protac three to seven times to an IC50 
of 3.8 μM at 72 h and an IC50 of 0.216 μM at 144 h (Figure 6a). Growth of PC-3 cells was not 
affected by Protac-AA at concentrations that suppressed the growth of LNCaP cells (Figure 
6a). The new peptide by itself (that is without the DHT ligand; Leu-Ala-Pro(OH)-Tyr-Ile-
Gly-Gly-(D-Arg)9) did not affect proliferation of LNCaP cells (Figure 6a). Thus, the 
polyarginine tail increased the activity of the Protac without altering its specificity.
To determine the effects of Protac-AA on AR levels, we treated LNCaP cells and examined 
AR expression. Protac reduced the protein level of AR, which was associated with activation 
of pRb (Figure 6b). Dephosphorylation of pRb was correlated with cell cycle arrest in G1 
(Figure 6c), which was also observed with Protac-A treatment and with androgen 
deprivation (Figure 4b; Knudsen et al., 1998). This more active Protac also induced a 
reduction in the number of viable cells after prolonged treatment (Figure 6d), suggesting the 
possibility of specific toxicity similar to previous reports where AR was downregulated by 
siRNA for several days (Linja et al., 2001; Eder et al., 2002; Zegarra-Moro et al., 2002; Liao 
et al., 2005). These results demonstrate that a Protac that was modified to enhance its 
permeability in cells maintained high affinity interaction and specificity for its target protein.
Discussion
Inhibiting AR or ERα activity has become one of the major goals in controlling the growth 
of hormone-dependent prostate or breast tumors, respectively. A main objective of the 
pharmaceutical and biotechnology industries is to isolate compounds that inhibit proteins 
like AR and ERα that contribute to disease. A common way of doing this is to develop an in 
vitro or in vivo high-throughput screening assay for the protein of interest, and then to 
screen large libraries of natural or man-made compounds for those that inhibit the targeted 
function (Broach and Thorner, 1996). A second approach is to employ structure-based drug 
design to create a molecule that will insinuate itself into the active site of the target 
(Blundell, 1996; Hogan, 1996; Verdine, 1996). Although these methods represent the current 
state-of-the-art in drug discovery, they both suffer from serious limitations. First, both are 
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laborious, expensive and frequently fail to identify a good lead compound that inhibits the 
desire target. Second, by their very nature, high-throughput screens are typically limited to 
identifying substances that interact with the target in a functionally relevant manner. Given 
that the active site of an enzyme compromises only a small fraction of its total surface area, 
many compounds that can bind a target may escape detection in these assays. Third, a 
corollary to the previous limitation is that both high-throughput screens and structure-based 
drug design are suitable only for proteins with readily assayable activities or well-defined 
active sites. To address some of these limitations we have developed Protacs that can be used 
to downregulate any protein that has a known ligand, regardless of whether the target has 
assayable activity.
In this work, we employed Protacs to downregulate the ERα and AR in breast and prostate 
cancer cells, respectively. Our results demonstrated that Protacs can induce chemical 
knockdown of these oncogenic proteins with specificity dictated by the physiologic ligand of 
the selected target. Furthermore, chemical knockdown was achievable by Protac-dependent 
ubiquitination and proteasome-dependent degradation of endogenous AR and ERα. Our data 
also showed that the decrease in ERα levels interfered with receptor signaling as measured 
by reduced expression of the target genes cyclin D1 and PR A and B. The effects of Protacs 
in receptor signaling were inhibited by competition with E2 or DHT demonstrating again the 
specificity of Protacs to their targets. We observed that, whereas Protac-B treatment induces 
a dramatic reduction on ERα levels, the addition of E2 in competition with Protac-B seemed 
to partially decrease the downregulation of receptor levels (Figure 4a). A possible 
explanation for the lack of a synergistic effect would be that estradiol stimulation induces 
approximately 50% decrease in ERα levels as it has been shown in previous studies (Pink 
and Jordan, 1996). After this decrease in receptor levels, a stable steady-state level of 
receptor expression is established during the continued presence of estradiol, which does not 
happen with Protacs treatment. These observations would explain why ERα degradation 
induced by E2 was less than that induced by Protac (Figure 4a). The addition of estradiol to 
Protac-B treatment could result in a competition between them to bind to the same domain 
in the receptor thereby inducing two different rates of degradation. The combined treatment 
of both E2 and Protac-B lead to greater degradation than with E2 treatment alone, but less 
ERα degradation than with only Protac-B treatment (Figure 4a). Estradiol binding to ERα is 
known to result in ERα ubiquitination for 26S proteasome degradation (Wijayaratne and 
McDonnell, 2001; Preisler-Mashek et al., 2002). ERα degradation by the proteasome has 
also been closely linked to ERα transcriptional activation (Lonard et al., 2000; Reid et al., 
2003) but this has been controversial depending on the model system (Alarid et al., 2003; 
Fan et al., 2004; Duong et al., 2007). Although we observed ubiquitin-dependent 
degradation of ERα following Protac treatment, this does not imply that estrogen specific 
genes are transcribed (Figure 4a).
In addition to the proximal effects on receptor signaling, treatment with Protacs also led to 
dephosphorylation of pRb and cell cycle arrest in G1. Importantly, Protacs had no effect on 
the proliferation of hormone-independent breast and prostate cancer cell lines, documenting 
the specificity of their action.
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It is interesting to consider how Protacs compare to other approaches for abrogating 
hormone receptor signaling activity. The effects of ERα-directed Protac are in agreement 
with those that described a decrease in cyclin D1 gene expression and pRb phosphorylation, 
and G0/G1 cell arrest in MCF-7 cells treated with the pure antiestrogens ICI 182780 and ICI 
164384 (Doisneau-Sixou et al., 2003). Like the ERα-directed Protac described here, pure 
antiestrogens also induces ERα degradation (Dauvois et al., 1992; Borras et al., 1996; Pink 
and Jordan, 1996), and the loss of ERα not only abrogates the transcriptional effect of 
estrogen, but also blocks the activation of ERα by other growth factors (Rau et al., 2005). 
Previous work has demonstrated that knocking down AR by siRNA in hormone-dependent 
cells resulted in cell cycle arrest over a longer period of time (beyond 72 h) and apoptosis 
after G1 arrest (Linja et al., 2001; Eder et al., 2002; Zegarra-Moro et al., 2002; Liao et al., 
2005). Similar responses were observed upon extended incubation of hormone-dependent 
prostate cancer cells with AR-targeted Protac. It is notable that many prostate refractory 
tumors still require AR. AR is overexpressed or mutated in these cells such that it remains 
functional but its affinity for or response to ligands is altered (Culig et al., 1994; Gaddipati et 
al., 1994; Bubendorf et al., 1999; Craft et al., 1999; Taplin et al., 1999; Godoy-Tundidor et 
al., 2002; Ueda et al., 2002; Bakin et al., 2003; Franco et al., 2003). Extended antihormonal 
therapy of breast and prostate cancer can select for a subpopulation of tumor cells in which 
the drug acts as an agonist instead of an antagonist—as in the case of flutamide in prostate 
cancer or tamoxifen in breast cancer (Rau et al., 2005), resulting in progression of disease 
and death (Culig et al., 1999; Taplin et al., 1999). Protac technology could potentially be 
useful in treating these classes of disease (mutated or overexpressed receptor but still with 
affinity for the ligand) because the inhibitory effect on receptor activity is based on the 
induction of receptor degradation. In many cases the overexpression of AR and ERα in 
prostate and breast cancer confers resistance to hormone therapy. Theoretically, in those 
cases Protac would reduce the receptor levels, as we have shown in tumor cell lines. Our 
finding that receptor degradation by Protac appears to be independent of the relative levels 
of receptor expression suggests that reduction in receptor levels might increase the 
sensitivity of tumor cells to hormone therapy. In those cases that the resistance is because of 
simple receptor overexpression, the best case scenario is that Protac treatment alone blocks 
receptor signaling.
Although these results are promising, the concentrations of Protacs required for growth 
inhibition are too high for in vivo studies in preclinical animal models. To address this 
problem, we modified the Protacs to determine whether their cell permeability could be 
enhanced without compromising affinity or specificity for the target protein. We added a 
polyarginine tail that should improve the permeability and increase the solubility of Protacs 
(Kirschberg et al., 2003). The polyarginine-containing Protac bound with good affinity to 
VHL and induced the downregulation of AR and G1 arrest, albeit at 3- to 4-fold lower 
concentrations than the original Protac-A. Future work will focus on the development of 
multiple Protacs that can potentially target additional proteins that contribute to the growth 
of cancer cells.
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Materials and methods
Cell cultures
All cell lines used in this study were maintained under standard conditions of temperature 
(37 °C), humidity (95%) and carbon dioxide (5%). The following cell lines were used: 
LNCaP (American Type Culture Collection (ATCC) number CRL-1740), PC-3 (ATCC 
number CRL-1435), DU-145 (ATCC number HTB-81), T47D (ATCC number HTB-133), 
MCF-7 (ATCC number HTB-22) and SKBr-3 (ATCC number HTB-30). They were 
maintained in phenol-red-free RPMI 1640 (Gibco number 11835) supplemented with 10% 
of fetal bovine serum (FBS; Omega Scientific number FB-01) or 10% of charcoal dextran 
treated FBS (ctFBS; Omega Scientific number 800-799-5873). ctFBS signifies serum 
without steroids and it was used in experiments where we wanted to see the requirements of 
steroids by the different cell lines. The growth in this media (RPMI 1640, 10% ctFBS) was 
determined to assess hormone dependence.
Cell proliferation and viability assays
All proliferation assays were based on the (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide) (MTT) method. This was based on measuring living cells through 
mitochondrial dehydrogenase activity (Sigma Inc., Saint Louis, MO, USA). Cells were 
plated in a 96-well, 10 000 cells per 100 μl/well. After 24–48 h of being plated, the cells 
were treated with Protac. New media and Protac were replaced after 72 h of experiment 
when experiments were longer than 72 h. At the end of the experiment, the media was 
removed and dimethyl sulfoxide was added as MTT solubilization solution. Absorbance was 
measured at 550 nm.
Peptides, drugs and compounds
We used different compounds for different treatments. MG 132 is a proteasome inhibitor 
(Calbiochem Inc., Gibbstown, NJ, USA). β-Estradiol was purchased from Sigma-Aldrich 
Inc. (Saint Louis, MO, USA). All peptides were purchased from GL Biochem Ltd 
(Shanghai, China); pentapeptide-G-G-[Arg]9=(H-Leu-Ala-Pro(OH)-Tyr-Ile-Gly-Gly-[D-
Arg]9-OH) and mutant pentapeptide-G-G-[Arg]9=(H-Leu-Ala-Ala-Tyr-Ile-Gly-Gly-[D-
Arg]9-OH). Protac was synthesized by coupling β-estradiol to the pentapeptide and 
pentapeptide-G-G-[Arg]9 as referenced before (Sakamoto et al., 2003; Bargagna-Mohan et 
al., 2005).
Western blot analysis
Cells were lysed in radio immunoprecipitation assay (RIPA) buffer (Sigma Inc.) with 
protease inhibitor cocktail (Sigma Inc.) and phosphatase inhibitor cocktail (Sigma Inc.). 
Lysates were centrifuged at 14 000 g for 20 min and quantified using the bicinchoninic acid 
protein assay kit (Pierce Inc., Rockford, IL, USA). The same amount of protein was loaded 
on SDS–polyacrylamide gels and proteins were transferred onto nitrocellulose membranes. 
The following antibodies were used: anti-AR (Upstate Biotechnology Inc., Temecula, CA, 
USA), anti-ERα (Upstate Biotechnology Inc.), anti-β-tubulin (Sigma Inc.), anti-cyclin D1 
(Sigma Inc.), anti-HIF-1α (BD Transduction Lab., Franklin Lakes, NJ, USA), anti-ubiquitin 
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(Sigma Inc.) and anti-phospho-Rb and anti-PR (Cell Signaling Inc., Danvers, MA, USA). 
The used secondary antibodies were purchased from Santa Cruz Biotechnologies Inc. (Santa 
Cruz, CA, USA). Enhanced chemiluminescence was used to detect signal.
Immunoprecipitations
To immunoprecipitate ERα and AR, we lysed cells (107) with RIPA buffer. Ten microliters 
of anti-ERα or anti-AR (Upstate Biotechnology Inc.) were incubated with 60 μl of washed 
protein A agarose bead slurry (Upstate Biotechnology Inc.) in 500 μl of phosphate buffered 
saline (PBS) for 1 h at 4 °C. After washing the agarose beads, we diluted the cell lysate to 
roughly 1 μg/μl total cell protein with PBS adding 1mg of protein from cell lysates to the 
reaction mixture, which was rocked gently overnight at 4 °C. Beads were precipitated and 
resuspended in 60 μl of 2× Laemmli sample buffer and boiled for 5 min. Finally, we 
collected the beads and used the supernatant to perform SDS–polyacrylamide gel 
electrophoresis and immunoblot analysis as described above.
Flow cytometry
Cells were plated at a density of 30 000 cells per cm2 per 600 μl (the same ratio as with 
proliferation assays). The treatments started 24–48 h after being plated. Cells were 
trypsinized and centrifuged at 250 g for 5 min, fixed in ethanol at 70%, and kept at −20 °C. 
Right before running the samples in the flow cytometer, the samples were stained by the 
addition of 1 ml of (3.4mM C6H5Na3O7, Triton X-100 0.3%, propidium iodide 0.1 mg/ml, 
ribo-nuclease A 20 μg/ml). The flow cytometer was a BD FACs SCAN and the analysis 
software was FlowJo 8.4.1.
Competitive binding assays
Peptide or Protac-AA stocks were diluted in assay buffer (50mM N-2-hydroxyethyl-
piperazine-N-2-ethanesulfonic acid pH 7.5, 50mM KCl, 20% glycerol) to 560 μM. Eleven 1:3 
serial dilutions (140 μM down to 2.4 nM final assay concentration) were performed and 5 ul 
of each dilution was mixed with 10 ul of VHL-Elongin B-Elongin C protein complex (1 uM 
final concentration in assay buffer) and 5 ul of HIF-fluorescein (HIF—sequence Asp-Glu-
Ala-Leu-Ala-Pro(OH)-Tyr-Ile-Pro-Asp, fluorescein added at N terminus; 12.5 nM final 
concentration in assay buffer). This volume was placed in a 384 well plate (Corning, Lowell, 
MA, USA, Catalog number 3654) in triplicate. The plate was incubated in the dark at room 
temperature for 1 h to stabilize the signals, and then read on an Envision plate reader 
(PerkinElmer, Waltham, MA, USA; polarized filters—excitation filter 480 nM, emission 
filters 535 nM). IC50 numbers determined using XLFit Excel Add-in (IDBS, Guildford, UK).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Proteolysis targeting chimeric molecule (Protac) model. (a) Two moieties form the chimeric 
compound (Protac). The first moiety is the activated degron, hydroxylated pentapeptide of 
hypoxia-inducible factor-1α (HIF-1α) that would recruit the activity of Von –Hippel–
Lindau ubiquitin ligase (E3). The second moiety is the natural ligand of the target that we 
wish to degrade, Estradiol for estrogen receptor-α or dihydroxytestosterone for androgen 
receptor. This heterobifunctional small molecule is a specific bridging molecule for protein 
degradation. Ub stands for ubiquitin. (b) Protacs-A and B. The specificity is because of the 
ligand that interacts with the target. The ubiquitin ligase activity is recruited by the 
hydroxypentapeptide of HIF 1α.
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Figure 2. 
Specific effect of proteolysis targeting chimeric molecule (Protac) treatment in prostate and 
breast cancer cell lines. (a) Effects of Protac-A treatment for 72 h on proliferation of prostate 
cancer cell lines. IC50=12.5 μM for LNCaP cells, whereas PC-3 cells were not affected at the 
same concentrations. (b) Effects of Protac-B on proliferation of breast cancer cell lines. 
MCF-7 and T47D had an IC50=50 μM and IC50=16 μM, respectively, whereas SKBr-3 was 
not affected at the same concentrations. Neither dihydroxytestosterone nor estradiol affected 
the proliferation of cells at the same concentrations used for Protacs. (c) Effects of Protacs 
on receptor protein levels. LNCaP or T47D cells were treated for 72 h with increasing 
concentrations of Protac-A or -B, respectively. The proliferation in all cases was measured 
by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) method. 
Absorbance at 550nm corresponds to living cells. The graphs show the mean values of a 
single experiment performed in triplicate, representative of three independent experiments.
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Figure 3. 
Proteolysis targeting chimeric molecules (Protacs) induce ubiquitination and proteasome-
dependent degradation. (a) Western blot analysis with androgen receptor (AR), estrogen 
receptor-α (ERα), β-tubulin antisera after treatment with Protac-B. LNCaP and MCF-7 
were treated with 50 μM of Protac-B for 24 h. (b) Western blot analysis with anti-ERα, β-
tubulin and hypoxiainducible factor-1α antisera and lysates from MCF-7 and T47D cells. 
Cells were treated with MG132, and Protac-B for 6 h at the indicated concentrations. (c) 
Immunoprecipitation with anti-ERα antisera and immunoblot with anti-ERα and ubiquitin 
antisera. T47D were treated for 6 h with Protac-B and MG132 at the indicated 
concentrations. The graph corresponds to densitometry of the shown ubiquitinated ERα 
western blot. (d) Immunoprecipitation with anti-AR antisera and immunoblot with anti-AR 
and ubiquitin antisera. LNCaP cells were treated for 6 h with Protac-A and MG132 at the 
indicated concentrations. The graph corresponds to densitometry of the shown ubiquitinated 
AR western blot. These experiments were repeated three times.
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Figure 4. 
Proteolysis targeting chimeric molecule (Protac) treatment induces cell cycle arrest in 
hormone-dependent cell lines. (a) Expression of protein levels of phosphorylated 
retinoblastoma (Rb), β-tubulin, progesterone receptor, cyclin D1 and estrogen receptor-α 
after treating T47D and MCF-7 cells with Protac-B for 6 h. (b) Comparison of cell cycle 
profile corresponding to LNCaP cells treated with Protac-A for 72 h. Cells were stained with 
propidium iodide. Expression of protein levels of phosphorylated Rb and β-tubulin in 
LNCaP cells after being treated with Protac-A during 6 h. (c) LNCaP cell growth after 6 
days of treatment with Protac-A. (}*) indicates the decrease in cell viability during the past 
72 h of treatment. The proliferation in all cases was measured by 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide (MTT) method. Absorbance at 550nm corresponds to 
living cells. The graph shows mean values of a single experiment performed in triplicate, 
representative at least of three independent experiments with similar results.
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Figure 5. 
Modification of proteolysis targeting chimeric molecule (Protac) to target androgen receptor. 
(a) Scheme of molecular structure of Protacs-A turning into Protacs-AA after the addition of 
a -G-G-[Arg]9 (polyarginine tail) to the pentapeptide. (b) Competitive binding assay with 
Von –Hippel–Lindau (VHL). Fluorescent hypoxia-inducible factor-1α (HIF-1α; Asp-Glu-
Ala-Leu-Ala-Pro(OH)-Tyr-Ile-Pro-Asp-FITC) is the control competitor for the union with 
VHL ubiquitin ligase. HIF-1α: (Asp-Glu-Ala-Leu-Ala-Pro(OH)-Tyr-Ile-Pro-Asp). 
Pentapeptide-Gly-Gly-[D-Arg]9: Leu-Ala-Pro(OH)-Tyr-Ile-Gly-Gly-[D-Arg]9. Mutated 
pentapeptide-Gly-Gly-[Arg]9: Leu-Ala-Ala-Tyr-Ile-Gly-Gly-[D-Arg]9. Represented in the 
graphs are mean values of a single experiment performed in triplicate, representative of three 
independent experiments with similar results. Standard deviations were less than 10% of the 
total value in each point. Ki’s were estimated by interpolation and represent the Ki’s of the 
shown experiment.
Rodriguez-Gonzalez et al. Page 18
Oncogene. Author manuscript; available in PMC 2017 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. 
Proteolysis targeting chimeric molecule (Protac) AA activity in prostate cancer cell lines. (a) 
LNCaP and PC-3 cells were treated for 72 h at increasing concentrations of Protac-AA. 
LNCaP cell growth was inhibited at an IC50=3.8 μM, whereas PC-3 cells were not affected. 
LNCaP cells were also treated with increasing concentrations of pentapeptide-G-G-[Arg] 
with no growth inhibition at the same range of concentrations. (b) Expression of androgen 
receptor, phosphorylated retinoblastoma and β-tubulin protein levels in LNCaP cells treated 
for 72 h with increasing concentrations of Protac-AA. (c) Comparison of cell cycle profile 
corresponding to treated and untreated LNCaP cells with Protac-AA during 72 h. DNA was 
stained using propidium iodide. (d) Viable cells after 6 days of treatment of LNCaP cells 
with Protac-AA. (}*) indicates the decrease in cell viability during the past 72 h of 
treatment. Measurement of viable cells was performed by 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) method. Absorbance at 550nm corresponds to living 
cells. The graph shows mean values of a single experiment performed in triplicate, 
representative at least of three independent experiments with similar findings. IC50’s were 
estimated by interpolation and represent the mean of four independent experiments 
performed in triplicate.
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